Isomangiferin Attenuates Renal Injury in Diabetic Mice via Inhibiting Inflammation
- Diabetes Metab Syndr Obes. 2020 Nov 10:13:4273-4280. doi: 10.2147/DMSO.S276229.
- 1. Department of Pharmacology, School of Pharmacy, China Pharmaceutical University, Nanjing, People's Republic of China.
- 2. Department of Acupuncture, Jurong Hospital Affiliated to Jiangsu University, Zhenjiang, People's Republic of China.
- 3. Department of Pharmacy, Kangda College of Nanjing Medical University, Lianyungang, People's Republic of China.
- 4. Department of Neurosurgery, Sir Run Run Hospital, Nanjing Medical University, Nanjing, People's Republic of China.
- # Contributed equally.
Aim: Renal injury induced by diabetes is reported to be associated with inflammation. Isomangiferin (ISO), a xanthone C-glucoside from the Cyclopia subfamily, exhibits many pharmacological properties. This study aimed to evaluate the protection of ISO against renal damage in diabetic mice.
Methods: Serum glucose, Insulin, uric acid, creatinine, total Cholesterol (TC), triglyceride (TG), and inflammatory cytokines in serum and the kidney of db/db diabetes model mice were detected. The components of high mobility group protein B1 (HMGB1)/NACHT leucine-rich repeat- and PYD-containing 3 (NLRP3)/nuclear factor kappa-B (NF-κB) pathway in the kidney were detected by Western blot and immunohistochemical analysis.
Results: ISO improved lipid profile and glucose tolerance, and inhibited the production of inflammatory cytokines in a db/db model mice. Moreover, ISO decreased biochemical indexes in the serum and inhibited the activation of HMGB1/NLRP3/NF-κB signaling in the kidney of db/db model mice.
Conclusion: ISO provides protection against renal injury via inhibiting HMGB1/NLRP3/NF-κB signaling in a diabetic mouse model.
-
Cat. No.Product NameDescriptionTargetResearch Area
-